• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » First vaccine for fatal visceral leishmaniasis enters clinical trial

First vaccine for fatal visceral leishmaniasis enters clinical trial

February 27, 2012
CenterWatch Staff

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

The phase I trial is taking place in Washington state, while a companion phase I trial is being planned in India—an epicenter of VL, which destroys white and red blood cells and if left untreated has a 90% case fatality.

The IDRI vaccine, known as LEISH-F3 + GLA-SE, is a highly purified, recombinant vaccine.  It incorporates two fused leishmania parasite proteins and a powerful adjuvant to stimulate an immune response against the parasite.

"With this clinical trial, we hope to launch a new era in the fight against visceral leishmaniasis," said Franco Piazza, medical director at IDRI and leader of the vaccine's clinical development.  "For the first time, an advanced vaccine to prevent this devastating disease is being tested in people."

The U.S. phase I clinical trial will consist of 36 adult volunteers randomly assigned to receive one of three versions of the vaccine, which differ in the amount of adjuvant included. The trial will evaluate the safety and immunogenicity of each version.

The Indian phase I trial will be led by Gennova in collaboration with the Banaras Hindu University in Varanasi, India, in the former’s new, neglected-disease vaccine formulation center. Beginning later in 2012, Gennova will produce the LEISH-F3 + GLA-SE vaccine using IDRI technology and then begin testing in healthy Indian adults.

Subsequent clinical trials will involve larger numbers of people who are at high risk of developing VL during their daily lives because they are frequently bitten by sand flies. IDRI believes only such large trials, conducted in real-life situations of disease exposure, will determine the full effectiveness of the LEISH-F3 + GLA-SE vaccine.

Both phase I trials are being funded by the Bill & Melinda Gates Foundation.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing